S182: TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL‐1.

MLA

Minnema, M. C., et al. “S182: Talquetamab, a G Protein‐Coupled Receptor Family C Group 5 Member D X Cd3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: Updated Efficacy and Safety Results from Monumental‐1.” HemaSphere, vol. 6, June 2022, pp. 83–84. EBSCOhost, https://doi.org/10.1097/01.HS9.0000843620.09412.35.

APA

Minnema, M. C., Krishnan, A., Berdeja, J. G., Oriol, A., van de Donk, N. W., Rodríguez, O. P., Morillo, D., Mateos, M. ‐V., Costa, L. J., Caers, J., Vishwamitra, D., Ma, J., Yang, S., Hilder, B. W., Tolbert, J., Goldberg, J. D., & Chari, A. (2022). S182: Talquetamab, a G Protein‐Coupled Receptor Family C Group 5 Member D X Cd3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: Updated Efficacy and Safety Results from Monumental‐1. HemaSphere, 6, 83–84. https://doi.org/10.1097/01.HS9.0000843620.09412.35

Chicago

Minnema, M. C., A. Krishnan, J. G. Berdeja, A. Oriol, N. W. van de Donk, Otero, P. Rodríguez, D. Morillo, et al. 2022. “S182: Talquetamab, a G Protein‐Coupled Receptor Family C Group 5 Member D X Cd3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: Updated Efficacy and Safety Results from Monumental‐1.” HemaSphere 6 (June): 83–84. doi:10.1097/01.HS9.0000843620.09412.35.